AzurBio Pharma

Empowering biopharmaceutical companies with a 1st life-changing medicine to expand to Europe.

 

Contact us

Europe. A fantastic opportunity for biopharmaceutical companies.

EU is the

2nd*

largest market globally

for prescription medicines

*23% Europe - Deloitte, 2023

Europe. A challenging and complex market to address.

Europe is Not a country

  • Multiple regulatory and market access environments vs the US
  • Market differences between individual European countries

Need Expertise and focused efforts to

  • Understand Europe as a whole & as individual markets
  • Adopting a strategic approach to market prioritization

Our Solutions.

We provide innovative solutions to enter the EU market by maximizing flexibility and minimizing operational burden, from registration through to commercialization. 

Expand to Europe

A unique partnership model that goes beyond traditional full outsourcing or licensing agreements.

flag-france
flag-italie
Available Soon
flag-espana
Available Soon
flag-england
Available Soon
flag-allemagne
Available Soon

Unlock an EU country

Unlock France

Flexible Turnkey solutions to swiftly establish your locally compliant organization, surpassing conventional models.

flag-france

Early Access Program

A unique, all-in-one solution for launching an early access program in one of Europe's most supportive regulatory environments

Our Clients. Innovators in rare or serious diseases.

Group 372@3x

AzurBio Pharma. The partner of choice for biopharmas.

tour-effel
  • Paris (Headquarter)
  • Nice
  • Zug
statue-liberte
  • Boston
  • New York

Our Strategic Committee. Seasoned Industry Experts.

team-5
Corinne Schmitz
Chairman, Founder & CEO at AzurBio Pharma
team-2
Antoine Barouky
Former VP General Manager EU at Alnylam
team-3
Marc Lefrançois
Health Industry Partner at CMI
team-1
Stéphane André
Former SVP Head of Global Regulatory Affairs at Ipsen
team-4
Marlène Schuppli Nollet
Senior Director, Business Development & Alliances

Looking to enter the EU market?
Contact us today.